Erschienen in:
01.06.2009 | Original Article
Protein kinase C-beta II (PKC-βII) expression in patients with colorectal cancer
verfasst von:
Karen-Lise Garm Spindler, Jan Lindebjerg, Michael Lahn, Sanne Kjaer-Frifeldt, Anders Jakobsen
Erschienen in:
International Journal of Colorectal Disease
|
Ausgabe 6/2009
Einloggen, um Zugang zu erhalten
Abstract
Purpose
Current development of targeted agents for the treatment of colorectal cancer include the clinical evaluation of kinase inhibitors, such as enzastaurin, a serine/threonine kinase inhibitor designed to suppress signaling through Protein Kinase C (PKC) and AKT pathways. Little is known about the expression of PKC-β in colorectal cancer or the prognostic value in colorectal cancer, which was the focus of the present study.
Methods
PKC-βII protein expression was examined in 99 primary colorectal adenocarcinomas and 33 corresponding regional lymph node metastases by immunohistochemistry (IHC). The PKC-βII immunoreactivity was mutually compared and correlated with survival information of all examined patients.
Results
Immunohistochemical expression of PKC-βII was detected in 18/99 carcinomas (18.2%). There was no correlation between PKC-βII staining and traditional clinicopathological parameters. However the median survival was 2.2 years in PKC-βII expressing tumors compared to 5.4 in PKC-βII negative tumors (p = 0.25), with a trend for association to poor prognosis.
Conclusion
We here describe for the first time the immunohistochemical detection of PKC-βII in patients with colorectal cancer and show a trend associating with poor survival. The role of PKC-βII staining in colorectal tumors deserves further evaluation.